Quantcast

Senseonics begins US 180-day study of implantable monitor

The Germantown company that developed the only long-term implantable system for monitoring blood sugar has begun a clinical study to study its system when implanted for twice as long as is now allowed in the United States.

To purchase a reprint of this article, contact reprints@thedailyrecord.com.

Leave a Reply

Your email address will not be published. Required fields are marked *

*